Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell
transplant using related or unrelated donor in persons 0-70 years of age diagnosed with
dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized
by a requirement for red blood cell and platelet transfusions. Three different preparative
regimens are included based on disease and donor type.